Cipla invests $90 million in API plants; Isis gets EMA nod for California plant;

> In its annual report, India-based Cipla says it will invest about $89.9 million to build active pharmaceutical ingredients (API) facilities at Patalganga, Mumbai, Bengaluru, Karnataka, and Kurkumbh, Pune, India. Annual report

> The Medicines and Healthcare Products Regulatory Agency in the U.K. has updated its 45-year-old regulations over drug manufacturing and distribution. Story

> An Isis Pharmaceuticals plant in Carlsbad, CA, has received EMA approval in anticipation of launch in Europe of Kynamro, a lipid-lowering drug it is developing with Genzyme. Story

> Materia has extended for another decade an agreement with Sigma-Aldrich for global distribution of its catalyst technology. Item

And Finally... Japanese regulators have approved for distribution in Japan Teijin's Bonalon Jelly, the first time the osteoporosis drug has been manufactured in this form, the company says. Release

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.